title: Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
authors.affiliation: Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, the University of Hong Kong, China.
authors.forename: Harinder
authors.initials: H
authors.lastname: Gill
authors.affiliation: Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, the University of Hong Kong, China.
authors.forename: Cheuk-Him
authors.initials: CH
authors.lastname: Man
authors.affiliation: Department of Pathology, the University of Hong Kong, China.
authors.forename: Alvin H W
authors.initials: AH
authors.lastname: Ip
authors.affiliation: Department of Pathology, the University of Hong Kong, China.
authors.forename: William W L
authors.initials: WW
authors.lastname: Choi
authors.affiliation: Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, the University of Hong Kong, China.
authors.forename: Howard C H
authors.initials: HC
authors.lastname: Chow
authors.affiliation: Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, the University of Hong Kong, China.
authors.forename: Yok-Lam
authors.initials: YL
authors.lastname: Kwong
authors.affiliation: Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, the University of Hong Kong, China ayhleung@hku.hk.
authors.forename: Anskar Y H
authors.initials: AY
authors.lastname: Leung
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001374:Azacitidine / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D004334:Drug Administration Schedule; D004357:Drug Synergism; D015870:Gene Expression; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D051379:Mice; D009000:Monocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D009154:Mutation; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012074:Remission Induction; D000077157:Sorafenib; D016019:Survival Analysis; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D001374:Azacitidine
keywords: FLT3-ITD; Sorafenib; acute myeloid leukemia; azacitidine
references.citation: Am J Hematol. 2013 Jan;88(1):56-9
references.pmid: 23115106
references.citation: Leukemia. 2013 Feb;27(2):260-8
references.pmid: 22797419
references.citation: Blood. 2013 Jun 6;121(23):4655-62
references.pmid: 23613521
references.citation: J Clin Oncol. 2013 Sep 1;31(25):3110-8
references.pmid: 23897964
references.citation: Blood. 2012 Apr 5;119(14):3361-9
references.pmid: 22234690
references.citation: Blood. 2002 Jul 1;100(1):59-66
references.pmid: 12070009
references.citation: Cancer. 2010 Dec 1;116(23):5420-31
references.pmid: 20672358
references.citation: J Clin Oncol. 2010 Apr 10;28(11):1856-62
references.pmid: 20212254
references.citation: J Clin Oncol. 2013 Oct 10;31(29):3681-7
references.pmid: 24002496
references.citation: Blood. 2012 May 31;119(22):5133-43
references.pmid: 22368270
references.citation: Leukemia. 2012 Sep;26(9):2061-8
references.pmid: 22627678
references.citation: J Clin Oncol. 2010 Oct 1;28(28):4339-45
references.pmid: 20733134
references.citation: Blood. 2002 Dec 15;100(13):4372-80
references.pmid: 12393388